Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.Results from the global COAST 1 phase 3 study showed that amlitelimab met all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful skin clearance and diseas ...